MetaCap

Inhibrx Biosciences (INBX) News

NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

68.97-5.36 (-7.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INBX news summary

We found 7 recent headlines mentioning Inhibrx Biosciences (INBX): 1 in the past week and 4 in the past 30 days, most often from PR Newswire, Nasdaq, Seeking Alpha. INBX is making an outsized move today, down 7.21% at $68.97, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma", was published by PR Newswire on Nov 17, 2026.

Headlines link to the original publishers. MetaCap does not republish third-party articles.

Summary generated from market data by MetaCap's automated system. Methodology

Latest Inhibrx Biosciences headlines

Stocks mentioned alongside INBX

Compare INBX